Yong Park |
10 Articles |
|
Hemato-oncology
Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study
Ho-Young Yhim, Yong Park, Jeong-A Kim, Ho-Jin Shin, Young Rok Do, Joon Ho Moon, Min Kyoung Kim, Won Sik Lee, Dae Sik Kim, Myung-Won Lee, Yoon Seok Choi, Seong Hyun Jeong, Kyoung Ha Kim, Jinhang Kim, Chang-Hoon Lee, Ga-Young Song, Deok-Hwan Yang, Jae-Yong Kwak
Korean J Intern Med. 2024;39(3):501-512. Published online January 30, 2024
Background/Aims: Optimal risk stratification based on simplified geriatric assessment to predict treatment-related toxicity and survival needs to be clarified in older patients with diffuse large B-cell lymphoma (DLBCL).
Methods: This multicenter prospective cohort study enrolled newly diagnosed pat..
|
|
|
The effect of the response to the coronavirus disease pandemic on treatment outcomes in patients with lymphoma and multiple myeloma
Ka-Won Kang, Byung-Hyun Lee, Min Ji Jeon, Eun Sang Yu, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Chul Won Choi, Yong Park, Byung Soo Kim
Korean J Intern Med. 2021;36(6):1459-1470. Published online October 21, 2021
Background/Aims: Relatively little data are available on how the response to the coronavirus disease 2019 (COVID-19) pandemic has affected treatment outcomes in patients receiving chemotherapy for lymphoma or multiple myeloma. We aimed to determine the effect of COVID-19 countermeasures on treatment..
|
|
|
Risk factors for neutropenic fever in non-Hodgkin’s lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis
Yu Ri Kim, Soo-Jeong Kim, Yong Park, Sung Yong Oh, Hwan-Jung Yun, Yeung-Chul Mun, Jin Seok Kim; the Korean Society of Hematology Lymphoma Working Party
Korean J Intern Med. 2021;36(5):1181-1189. Published online July 16, 2021
Background/Aims: Febrile neutropenia (FN) interferes with the proper chemotherapy dose density or intensity in non-Hodgkin’s lymphoma (NHL) patients. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) ± rituximab has an intermediate FN risk. Prophylactic granulocy..
|
|
|
The role of platelet function analyzer-200 in predicting perioperative bleeding risk
Eun Sang Yu, Min Ji Jeon, Ka-Won Kang, Byung-Hyun Lee, Eun Joo Kang, Yong Park, Se Ryeon Lee, Hwa Jung Sung, Chul Won Choi, Byung Soo Kim, Dae Sik Kim
Korean J Intern Med. 2020;35(5):1199-1209. Published online February 6, 2020
Background/Aims: Various preoperative screening tests, such as platelet count, prothrombin time, activated partial thromboplastin time, and bleeding time, have been widely used to evaluate the risk of bleeding during surgery. Use of platelet function analyzer (PFA)-100/200 for assessing platelet fun..
|
|
|
Immature platelet fraction based diagnostic predictive scoring model for immune thrombocytopenia
Min Ji Jeon, Eun Sang Yu, Ka-Won Kang, Byung-Hyun Lee, Yong Park, Se Ryeon Lee, Hwa Jung Sung, Soo Yong Yoon, Chul Won Choi, Byung Soo Kim, Dae Sik Kim
Korean J Intern Med. 2020;35(4):970-978. Published online April 10, 2020
Background/Aims: The diagnosis of immune thrombocytopenia (ITP) is based on clinical manifestations and there is no gold standard. Thus, even hematologic malignancy is sometimes misdiagnosed as ITP and adequate treatment is delayed. Therefore, novel diagnostic parameters are needed to distinguish IT..
|
|
|
Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
Se Ryeon Lee, Hojoon Choi, Byung Hyun Lee, Ka-Won Kang, Eun Sang Yu, Dae Sik Kim, Yong Park, Chul Won Choi, Byung Soo Kim, Hwa Jung Sung
Korean J Intern Med. 2019;34(6):1333-1346. Published online October 26, 2018
Background/Aims: Bortezomib plus melphalan-prednisone (VMP) is a standard treatment for multiple myeloma, particularly for patients who are ineligible for high-dose therapy. However, early discontinuation or treatment modification is often needed owing to adverse events. The aim of this study was to..
|
|
|
Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma
Dae Sik Kim, Eun Sang Yu, Ka-Won Kang, Se Ryeon Lee, Yong Park, Hwa Jung Sung, Chul Won Choi, Byung Soo Kim
Korean J Intern Med. 2017;32(4):711-721. Published online November 4, 2016
Background/Aims: The aims of this study were to identify the value of inflammatory markers as pretreatment prognostic factors for patients with multiple myeloma (MM) and to estimate the value of a prognostic index including these markers at diagnosis.
Methods: A total of 273 newly diagnosed MM pati..
|
|
|
Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications
Junghoon Shin, Youngil Koh, Jeonghwan Youk, Miso Kim, Byung Soo Kim, Chul Won Choi, Hwa Jung Sung, Yong Park, Sung-Soo Yoon, Inho Kim
Korean J Intern Med. 2017;32(4):722-730. Published online June 26, 2017
Background/Aims: Although multiple myeloma (MM) is typically a disease of the elderly, a certain subset of extremely young patients exists. It is necessary to establish clinicopathological characteristics for this population.
Methods: We reviewed the medical records of MM patients whose age was 40 ..
|
|
|
Assessment of bone marrow involvement in patients with lymphoma: report on a consensus meeting of the Korean Society of Hematology Lymphoma Working Party
Yong Park, Byung Bae Park, Ji Yun Jeong, Wook Youn Kim, Seongsoo Jang, Bong Kyung Shin, Dong Soon Lee, Jae Ho Han, Chan-Jeoung Park, Cheolwon Suh, Insun Kim, Hyun-Sook Chi
Korean J Intern Med. 2016;31(6):1030-1041. Published online November 1, 2016
In September 2011, the Korean Society of Hematology Lymphoma Working Party held a nationwide conference to establish a consensus for assessing bone marrow (BM) involvement in patients with lymphoma. At this conference, many clinicians, hematopathologists, and diagnostic hematologists discussed vario..
|
|
|
The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
Cheolsu Kim, Ho Sup Lee, Chang-Ki Min, Je Jung Lee, Kihyun Kim, Dok Hyun Yoon, Hyeon Seok Eom, Hyewon Lee, Won Sik Lee, Ho-Jin Shin, Ji Hyun Lee, Yong Park, Jae-Cheol Jo, Young Rok Do, Yeung-Chul Mun
Korean J Intern Med. 2015;30(5):675-683. Published online August 27, 2015
Background/Aims: The purpose of this study was to determine the correlations between inflammatory factors—including absolute lymphocyte count, lactate dehydrogenase, β2-microglobulin, albumin, C-reactive protein, and ferritin—and the prognosis for survival in patients with multiple myeloma (MM) ..
|
|
